

CLIA #: 31D2026917

PATIENT DEMOGRAPHICS

PATIENT INFORMATION:	PHYSICIAN INFORMATION:	SPECIMEN INFORMATION:
Patient, Test DOB: 1/1/1954 Gender/Age: M/68 SS#: UN:171550660	Test Physician Test Practice 300 Columbus Circle, Suite A, Edison, NJ 08837 866.909.PATH, Fax:9082721478	ACCESSION #: TS22-00534 PROCEDURE DATE: 12/18/2022 DATE RECEIVED: 12/19/2022 REPORTED ON: 12/20/2022

CLINICAL INFORMATION

PSA Level = 6.4 ng/mL Elevated PSA T2b ((based on biopsy results, actual clinical staging may vary)) Clinical Stage: T2b

FINAL DIAGNOSIS

(Based Upon Gross And Microscopic Examination)
Prostate Gland, Ultrasound Guided Needle Biopsies:

G: Right Apex: Adenocarcinoma of Prostate.
Gleason Score: 8(4+4). Involving 10% of total surface area, and 1 of 1 cores. Perineural invasion not seen.

Core#	Gleason Score	Grade Group	Tumor Length (cm)	Core Length (cm)	%
1	8(4+4)	4	0.2	1.5	10




I: Right Mid: Adenocarcinoma of Prostate.
Gleason Score: 6(3+3). Involving 70% of total surface area, and 1 of 1 cores. Perineural invasion present.


Core#	Gleason Score	Grade Group	Tumor Length (cm)	Core Length (cm)	%
1	6(3+3)	1	1.0	1.4	70

E: Left Base: Focus of atypical glands suspicious for adenocarcinoma.

- A: Left Apex: Benign prostatic tissue.**
- B: Left Lateral Apex: Benign prostatic tissue.**
- C: Left Mid: Benign prostatic tissue.**
- D: Left Lateral Mid: Benign prostatic tissue.**
- F: Left Lateral Base: Benign prostatic tissue.**
- H: Right Lateral Apex: Benign prostatic tissue.**
- J: Right Lateral Mid: Benign prostatic tissue.**
- K: Right Base: Benign prostatic tissue.**
- L: Right Lateral Base: Benign prostatic tissue.**

DIAGNOSTIC MAP





DIAGNOSIS SUMMARY

Specimen	Diagnosis	CGS*	GG**	PTI
G	Malignant	8(4+4)	4	10%
I	Malignant	6(3+3)	1	70%
E	ASAP			

*CGS: Composite Gleason Score, **Grade Group

COMMENTS

Specific immunostains P63 and P504S (AMACR) were performed on specimens G and I and the results support the above diagnosis in the presence of adequate controls. these tests were validated and their performance characteristics determined by QDx Pathology Service. They may not be cleared or approved by the U.S Food and Drug Administration. the FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes.

The new five-tiered prostate Grade Group system, as adopted by WHO, is defined such that each group is associated with a unique prognosis based on PSA biochemical recurrence as an endpoint.

- Grade Group 1: Gleason Score ≤ 6
- Grade Group 2: Gleason Score 7(3+4)
- Grade Group 3: Gleason Score 7(4+3)
- Grade Group 4: Gleason Score 8
- Grade Group 5: Gleason Scores 9-10

In a large (>3500 patients) single institutional study, the 5-year actuarial biochemical recurrence-free survival for biopsy Grade Groups 1-5 were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, in patients treated with radical prostatectomy.

Ref: A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur Urol. 2016;69(3):428-35. Independent surgical validation of the new prostate cancer Grade-Grouping system. BJU Int. 2016;118(5):763-769.

* Partin Table Reference: James Buchanan Brady Urological Institute, Johns Hopkins Medicine (<http://urology.jhu.edu/prostate/partintables.php>)

GROSS EXAMINATION

SPECIMEN	CORES	LENGTH	INK	SPECIMEN	CORES	LENGTH	INK
A: Left Apex	2	1.0,1.5 cm		G: Right Apex	2	1.5 cm	
B: Left Lateral Apex	2	0.5, 1.0 cm	Green	H: Right Lateral Apex	1	0.5, 1.0 cm	Green
C: Left Mid	2	1.5, 2.0 cm		I: Right Mid	1	1.4 cm	
D: Left Lateral Mid	2	1.5, 1.0 cm	Green	J: Right Lateral Mid	1	1.6 cm	Green
E: Left Base	2	1.0,1.0 cm		K: Right Base	2	2.0 cm	
F: Left Lateral Base	1	1.5 cm	Green	L: Right Lateral Base	1	1.6, 1.3 cm	Green

SPECIMENS RECEIVED: 12 containers. Fixative: 10% formalin.

BILLING CODES

CPT	ICD-10
88305 X 12	C61; N40.0
88344 x 2	Date of Procedure: 12/18/2022

ELECTRONICALLY SIGNED OUT BY

Test Pathologist

Test Pathologist